{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:01:49Z","timestamp":1794859309818,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The long-term outlook for patients grappling with lung cancer (LC) remains bleak, with lung adenocarcinoma (LUAD) emerging as the most predominant histological subtype. Our Mendelian randomization (MR) investigation spotlighted that heightened levels of the circulating protein serpin peptidase inhibitor family G1 (SERPING1) substantially mitigated LC risk. The fusion of multi-omics strategies unveiled that SERPING1 exhibited diminished expression in LUAD patients compared to healthy individuals both in tissues and serum, with LUAD individuals showcasing elevated SERPING1 expression demonstrating improved prognoses. Furthermore, SERPING1 expression exhibited a robust correlation with the efficacy of immunotherapy. Through meticulous in vivo and in vitro analyses, we unraveled that SERPING1 impeded the proliferation, migration, invasion and wound healing of LUAD cells via the tuberous sclerosis 2 (TSC2)\/mammalian target of rapamycin (mTOR) pathway. Mechanistically, WNT inhibitor- Specificity Protein (SP5) was delineated as facilitator of SERPING1 transcription by binding to the SERPING1 gene promoter. Intriguingly, aside from the association between SERPING1 and systolic blood pressure, glycosylated hemoglobin (HbA1c), type I diabetes, no discernible link between SERPING1 overexpression and heightened risks of other cardiometabolic conditions and diseases was evident. In summary, SERPING1 emerges as a novel tumor suppressor gene and SP5\/SERPING1\/TSC2 is a promising therapeutic target in the context of LUAD.<\/jats:p>","DOI":"10.1038\/s41419-025-07440-3","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T17:19:42Z","timestamp":1739812782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["WNT inhibitor SP5-mediated SERPING1 suppresses lung adenocarcinoma progression via TSC2\/mTOR pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Yefeng","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-9190","authenticated-orcid":false,"given":"Jian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"7440_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"7440_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584\u201394.","journal-title":"Mayo Clin Proc"},{"key":"7440_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","volume":"893","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1\u201319.","journal-title":"Adv Exp Med Biol"},{"key":"7440_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejca.2017.01.006","volume":"75","author":"D Walder","year":"2017","unstructured":"Walder D, O\u2019Brien M. Looking back and to the future: Are we improving \u2018cure\u2019 in non-small cell lung cancer? Eur J Cancer. 2017;75:192\u20134.","journal-title":"Eur J Cancer"},{"key":"7440_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Finan C, Gordillo-Maranon M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug target validation using Mendelian randomisation. Nat Commun. 2020;11:3255.","journal-title":"Nat Commun"},{"key":"7440_CR6","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1093\/brain\/awad070","volume":"146","author":"J Lin","year":"2023","unstructured":"Lin J, Zhou J, Xu Y. Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain. 2023;146:3364\u201372.","journal-title":"Brain"},{"key":"7440_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104494","volume":"89","author":"J Chen","year":"2023","unstructured":"Chen J, Xu F, Ruan X, Sun J, Zhang Y, Zhang H, et al. Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses. EBioMedicine. 2023;89:104494.","journal-title":"EBioMedicine"},{"key":"7440_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03115-y","volume":"21","author":"S Luo","year":"2023","unstructured":"Luo S, Lam HS, Chan YH, Tang CSM, He B, Kwok MK, et al. Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study. BMC Med. 2023;21:410.","journal-title":"BMC Med"},{"key":"7440_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104488","volume":"89","author":"S Yuan","year":"2023","unstructured":"Yuan S, Wang L, Zhang H, Xu F, Zhou X, Yu L, et al. Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases. EBioMedicine. 2023;89:104488.","journal-title":"EBioMedicine"},{"key":"7440_CR10","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.ajhg.2022.08.004","volume":"109","author":"CE Harlow","year":"2022","unstructured":"Harlow CE, Gandawijaya J, Bamford RA, Martin ER, Wood AR, van der Most PJ, et al. Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies. Am J Hum Genet. 2022;109:1638\u201352.","journal-title":"Am J Hum Genet"},{"key":"7440_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104199","volume":"83","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu X, Wang L, Li K, Sun Y, Xiao L, et al. Genetic insights into therapeutic targets for aortic aneurysms: a Mendelian randomization study. EBioMedicine. 2022;83:104199.","journal-title":"EBioMedicine"},{"key":"7440_CR12","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/gutjnl-2021-326070","volume":"72","author":"L Wang","year":"2023","unstructured":"Wang L, Liu Y, Dai Y, Tang X, Yin T, Wang C, et al. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut. 2023;72:958\u201371.","journal-title":"Gut"},{"key":"7440_CR13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s00125-022-05849-5","volume":"66","author":"Q Fu","year":"2023","unstructured":"Fu Q, Jiang H, Qian Y, Lv H, Dai H, Zhou Y, et al. Single-cell RNA sequencing combined with single-cell proteomics identifies the metabolic adaptation of islet cell subpopulations to high-fat diet in mice. Diabetologia. 2023;66:724\u201340.","journal-title":"Diabetologia"},{"key":"7440_CR14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s42003-022-04011-6","volume":"5","author":"P Baloni","year":"2022","unstructured":"Baloni P, Arnold M, Buitrago L, Nho K, Moreno H, Huynh K, et al. Multi-Omic analyses characterize the ceramide\/sphingomyelin pathway as a therapeutic target in Alzheimer\u2019s disease. Commun Biol. 2022;5:1074.","journal-title":"Commun Biol"},{"key":"7440_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ijc.34478","volume":"153","author":"E D\u2019Angelo","year":"2023","unstructured":"D\u2019Angelo E, Pastrello C, Biccari A, Marangio A, Sensi F, Crotti S, et al. An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5-fluorouracil. Int J Cancer. 2023;153:437\u201349.","journal-title":"Int J Cancer"},{"key":"7440_CR16","doi-asserted-by":"publisher","first-page":"366.e1-366.e9","DOI":"10.1016\/j.urolonc.2018.05.021","volume":"36","author":"S Peng","year":"2018","unstructured":"Peng S, Du T, Wu W, Chen X, Lai Y, Zhu D, et al. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression. Urol Oncol. 2018;36:366.e1-366.e9.","journal-title":"Urol Oncol"},{"key":"7440_CR17","doi-asserted-by":"publisher","first-page":"ra9","DOI":"10.1126\/scisignal.2000590","volume":"3","author":"HP Kuo","year":"2010","unstructured":"Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signal. 2010;3:ra9.","journal-title":"Sci Signal"},{"key":"7440_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3389\/fcimb.2017.00423","volume":"7","author":"H Yin","year":"2017","unstructured":"Yin H, Zhao L, Li S, Xu L, Wang Y, Chen H. Impaired Cellular Energy Metabolism Contributes to Duck-Enteritis-Virus-Induced Autophagy via the AMPK-TSC2-MTOR Signaling Pathway. Front Cell Infect Microbiol. 2017;7:423.","journal-title":"Front Cell Infect Microbiol"},{"key":"7440_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10654-015-0011-z","volume":"30","author":"S Burgess","year":"2015","unstructured":"Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Consortium E-I. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015;30:543\u201352.","journal-title":"Eur J Epidemiol"},{"key":"7440_CR20","doi-asserted-by":"crossref","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018;7:e34408.","DOI":"10.7554\/eLife.34408"},{"key":"7440_CR21","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/bioinformatics\/btq419","volume":"26","author":"RJ Pruim","year":"2010","unstructured":"Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336\u20137.","journal-title":"Bioinformatics"},{"key":"7440_CR22","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1038\/s41388-021-01853-y","volume":"40","author":"J Wu","year":"2021","unstructured":"Wu J, Li L, Zhang H, Zhao Y, Zhang H, Wu S, et al. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Oncogene. 2021;40:4413\u201324.","journal-title":"Oncogene"},{"key":"7440_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-0327-7_16","volume":"2120","author":"G Sturm","year":"2020","unstructured":"Sturm G, Finotello F, List M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods Mol Biol. 2020;2120:223\u201332.","journal-title":"Methods Mol Biol"},{"key":"7440_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/pai.12024","volume":"24","author":"L Schneider","year":"2013","unstructured":"Schneider L, Hurewitz D, Wasserman R, Obtulowicz K, Machnig T, Moldovan D, et al. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. Pediatr Allergy Immunol. 2013;24:54\u201360.","journal-title":"Pediatr Allergy Immunol"},{"key":"7440_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/pai.12425","volume":"26","author":"TJ Craig","year":"2015","unstructured":"Craig TJ, Schneider LC, MacGinnitie AJ. Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: a systematic review. Pediatr Allergy Immunol. 2015;26:537\u201344.","journal-title":"Pediatr Allergy Immunol"},{"key":"7440_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.119.040180","volume":"140","author":"M Chong","year":"2019","unstructured":"Chong M, Sjaarda J, Pigeyre M, Mohammadi-Shemirani P, Lali R, Shoamanesh A, et al. Novel drug targets for ischemic stroke identified through Mendelian randomization analysis of the blood proteome. Circulation. 2019;140:819\u201330.","journal-title":"Circulation"},{"key":"7440_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01229-9","volume":"15","author":"J Sun","year":"2023","unstructured":"Sun J, Zhao J, Jiang F, Wang L, Xiao Q, Han F, et al. Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome. Genome Med. 2023;15:75.","journal-title":"Genome Med"},{"key":"7440_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104432","volume":"88","author":"Y Li","year":"2023","unstructured":"Li Y, Sundquist K, Zhang N, Wang X, Sundquist J, Memon AA. Mitochondrial related genome-wide Mendelian randomization identifies putatively causal genes for multiple cancer types. EBioMedicine. 2023;88:104432.","journal-title":"EBioMedicine"},{"key":"7440_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1042\/bj2010061","volume":"201","author":"S Chesne","year":"1982","unstructured":"Chesne S, Villiers CL, Arlaud GJ, Lacroix MB, Colomb MG. Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1. Biochem J. 1982;201:61\u201370.","journal-title":"Biochem J"},{"key":"7440_CR30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jaci.2010.08.012","volume":"126","author":"AP Kaplan","year":"2010","unstructured":"Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol. 2010;126:918\u201325.","journal-title":"J Allergy Clin Immunol"},{"key":"7440_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13681","volume":"33","author":"R Lopez-Martinez","year":"2022","unstructured":"Lopez-Martinez R, Martinez-Borra J, Fernandez-Gonzalez P, Coto E, Toyos-Gonzalez P. Hereditary angioedema caused by a novel intronic variant of SERPING1. Pediatr Allergy Immunol. 2022;33:e13681.","journal-title":"Pediatr Allergy Immunol"},{"key":"7440_CR32","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jaip.2021.11.018","volume":"10","author":"ML Baeza","year":"2022","unstructured":"Baeza ML, Gonzalez-Quevedo T, Caballero T, Guilarte M, Lleonart R, Varela S, et al. Angioedema due to acquired deficiency of C1-inhibitor: a cohort study in Spain and a comparison with other series. J Allergy Clin Immunol Pract. 2022;10:1020\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"7440_CR33","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaci.2023.04.023","volume":"152","author":"LB Ryo","year":"2023","unstructured":"Ryo LB, Haslund D, Rovsing AB, Pihl R, Sanrattana W, de Maat S, et al. Restriction of C1-inhibitor activity in hereditary angioedema by dominant-negative effects of disease-associated SERPING1 gene variants. J Allergy Clin Immunol. 2023;152:1218\u20131236.e1219.","journal-title":"J Allergy Clin Immunol"},{"key":"7440_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/pai.13420","volume":"32","author":"AK Jindal","year":"2021","unstructured":"Jindal AK, Rawat A, Kaur A, Sharma D, Suri D, Gupta A, et al. Novel SERPING1 gene mutations and clinical experience of type 1 hereditary angioedema from North India. Pediatr Allergy Immunol. 2021;32:599\u2013611.","journal-title":"Pediatr Allergy Immunol"},{"key":"7440_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1018639","volume":"13","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Yang H, Ji G, Su S, Fan Y, Wang M, et al. Identification of hub genes for early detection of bone metastasis in breast cancer. Front Endocrinol. 2022;13:1018639.","journal-title":"Front Endocrinol"},{"key":"7440_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01940-0","volume":"23","author":"B Huang","year":"2024","unstructured":"Huang B, Ren J, Ma Q, Yang F, Pan X, Zhang Y, et al. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway. Mol Cancer. 2024;23:34.","journal-title":"Mol Cancer"},{"key":"7440_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10020-023-00722-6","volume":"29","author":"Z Wei","year":"2023","unstructured":"Wei Z, Xia K, Zheng D, Gong C, Guo W. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K\/AKT\/mTOR pathway. Mol Med. 2023;29:133.","journal-title":"Mol Med"},{"key":"7440_CR38","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201582R","volume":"37","author":"W Zhao","year":"2023","unstructured":"Zhao W, Yang H, Liu L, Qu X, Ding J, Yu H, et al. OASL knockdown inhibits the progression of stomach adenocarcinoma by regulating the mTORC1 signaling pathway. FASEB J. 2023;37:e22824.","journal-title":"FASEB J"},{"key":"7440_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2329372","volume":"25","author":"S Liu","year":"2024","unstructured":"Liu S, Chen X, Zhang L, Lu B. CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells. Cancer Biol Ther. 2024;25:2329372.","journal-title":"Cancer Biol Ther"},{"key":"7440_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01203-1","volume":"8","author":"IJ Huggins","year":"2017","unstructured":"Huggins IJ, Bos T, Gaylord O, Jessen C, Lonquich B, Puranen A, et al. The WNT target SP5 negatively regulates WNT transcriptional programs in human pluripotent stem cells. Nat Commun. 2017;8:1034.","journal-title":"Nat Commun"},{"key":"7440_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08242-2","volume":"10","author":"MC Vogg","year":"2019","unstructured":"Vogg MC, Beccari L, Iglesias Olle L, Rampon C, Vriz S, Perruchoud C, et al. An evolutionarily-conserved Wnt3\/beta-catenin\/Sp5 feedback loop restricts head organizer activity in Hydra. Nat Commun. 2019;10:312.","journal-title":"Nat Commun"},{"key":"7440_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1180191","volume":"13","author":"G Xia","year":"2023","unstructured":"Xia G, Wu S, Luo K, Cui X. By using machine learning and in vitro testing, SERPINH1 functions as a novel tumorigenic and immunogenic gene and predicts immunotherapy response in osteosarcoma. Front Oncol. 2023;13:1180191.","journal-title":"Front Oncol"},{"key":"7440_CR43","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2217\/imt-2017-0049","volume":"10","author":"R Gupta","year":"2018","unstructured":"Gupta R, Balduzzi J, Davis-Lorton M. C1-esterase inhibitor (Cinryze((R))) use in the treatment of pediatric hereditary angioedema. Immunotherapy. 2018;10:635\u201342.","journal-title":"Immunotherapy"},{"key":"7440_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18176\/jiaci.0653","volume":"31","author":"T Caballero","year":"2021","unstructured":"Caballero T. Treatment of hereditary angioedema. J Investig Allergol Clin Immunol. 2021;31:1\u201316.","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07440-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07440-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07440-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T17:19:44Z","timestamp":1739812784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07440-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7440"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07440-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest related to this research. The workflows of this study were created with biorender.com.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"GWAS and multi-omics studies used data readily available to the public; thus, informed consent and ethical approval were not required. In addition, the collection of tissues was approved by the Life Ethics Committees of Beijing Friendship Hospital, Capital Medical University, Beijing, China (protocol 2023-P2-299-02) and the collection of human plasma was approved by the Life Ethics Committees of the People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China (protocol KY- IIT-2024-111). All experiments were performed following relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"103"}}